Breast Cancer Metastasis Mimicking Osteoblastoma: The CT “Sequestralike Appearance” of a T12 Vertebral Lesion and the Role of MRI and 18F-FES PET/CT
Introduction: When a “Benign-Looking” Vertebral Lesion Is Not Benign
Back pain is one of the most common complaints encountered in clinical practice. In a young woman, particularly one in her twenties, the initial differential diagnosis often includes muscular strain, intervertebral disc disease, posture-related pain, or other benign musculoskeletal disorders.
But medical imaging can completely change the clinical question.
A small vertebral lesion may initially appear deceptively reassuring—or may resemble a rare benign bone tumor—until the patient's clinical history and tumor biology are incorporated into the interpretation.
This is precisely what makes the present case so instructive.
A woman in her late twenties presented with a history of persistent back pain. CT demonstrated an approximately 2-cm lucent lesion within the T12 vertebral body. The lesion contained a small internal osseous or calcific structure resembling a sequestrum. There was also cortical involvement and mild adjacent soft-tissue extension.
In a young adult with a solitary vertebral lesion, this combination naturally raises the possibility of an osteoblastoma.
MRI did not immediately resolve the problem. The lesion was T1 hypointense, showed intermediate-to-high signal on T2-weighted sequences, demonstrated enhancement, and was associated with surrounding marrow edema. These findings were compatible with an aggressive benign bone tumor such as osteoblastoma, but they were not sufficiently specific to establish a histologic diagnosis.
The diagnostic direction changed dramatically when the patient was found to have ER-positive, PR-positive, HER2-negative invasive ductal carcinoma of the breast.
At that point, the same T12 lesion had to be interpreted in a fundamentally different clinical context.
Subsequent ^18F-FES PET/CT demonstrated increased radiotracer uptake at the T12 lesion and revealed additional osseous lesions that had not been clearly recognized on the initial CT examination.
The final interpretation was breast cancer bone metastasis.
This case illustrates one of the most important principles in modern radiology:
A lesion should not be interpreted solely by what it resembles. It should be interpreted according to what it is most likely to represent in that particular patient.
The distinction is especially important when a rare imaging pattern—such as a sequestral-like appearance—is encountered.
Figure 1. Clinical Overview of the Case
Figure 1. Clinical overview of a young woman with chronic back pain and a T12 vertebral lesion initially resembling osteoblastoma but ultimately interpreted as breast cancer bone metastasis.
The overview image summarizes the diagnostic journey: chronic back pain led to CT and MRI evaluation, followed by recognition of the patient's breast cancer biology and subsequent ^18F-FES PET/CT examination.
The importance of this figure is not simply visual. It demonstrates the central concept of diagnostic anchoring.
If the imaging appearance is considered independently from the patient's clinical information, osteoblastoma appears reasonable.
If the imaging appearance is integrated with an ER-positive breast cancer diagnosis, metastatic disease becomes substantially more important.
1. What Is a Sequestralike Appearance?
The term sequestrum has a specific pathologic meaning.
A true sequestrum is a fragment of devitalized bone that has become separated from surrounding viable bone, classically encountered in osteomyelitis.
However, the radiologic expression “sequestralike appearance” does not necessarily mean that the internal structure is a true sequestrum.
Instead, it describes an imaging pattern in which a relatively dense osseous or calcific structure is surrounded by a relatively lucent region within a bone lesion.
On CT, the internal structure may resemble a small “button” of bone.
This explains the related term button sequestrum sign.
The important diagnostic message is:
Sequestral-like appearance is a pattern—not a diagnosis.
It may occur in infectious, inflammatory, benign neoplastic, malignant, and metastatic conditions. The original case material emphasizes that this appearance should not automatically be equated with osteomyelitis or osteoblastoma.
A radiologist therefore needs to ask several questions:
Is the lesion lucent, sclerotic, or mixed?
Is the internal density true mineralization or residual bone?
Is the cortex intact?
Is there cortical destruction?
Is there a soft-tissue component?
Is the lesion centered in the vertebral body or posterior elements?
Is there marrow edema?
Is there epidural extension?
Does the patient have a known malignancy?
Is the lesion solitary or multifocal?
Does molecular imaging support a specific tumor phenotype?
The answers are more important than the sequestral-like appearance itself.
2. Why Did the Lesion Initially Look Like Osteoblastoma?
The initial radiologic impression was understandable.
Osteoblastoma is an uncommon benign but potentially locally aggressive bone-forming tumor. It tends to occur in younger patients and has a recognized predilection for the spine and other portions of the axial skeleton.
Several features in this case supported that interpretation:
Young age
Vertebral location
Approximately 2-cm focal lesion
Lucent component
Internal mineralized/osseous density
Cortical involvement
Locally aggressive appearance
The combination is particularly persuasive when the lesion is interpreted without knowledge of the patient's breast cancer.
However, there was an important discordant feature.
The lesion was centered within the T12 vertebral body.
Spinal osteoblastomas frequently arise from posterior elements rather than presenting as an isolated vertebral-body-centered lesion. The source case therefore correctly emphasizes that the patient's age and morphology favored osteoblastoma, while the lesion location was less typical.
This is a classic example of how radiology interpretation should balance positive and negative evidence.
A diagnosis should not be selected merely because several findings fit.
The radiologist should also ask:
What does not fit?
3. Pathophysiology of Breast Cancer Bone Metastasis
Breast cancer is one of the solid malignancies with a strong tendency to metastasize to bone.
The biology is complex.
Breast cancer cells can disseminate from the primary tumor and enter the circulation, eventually reaching the bone marrow microenvironment. Some tumor cells may remain dormant for prolonged periods before becoming clinically detectable.
Bone metastasis is not simply a passive process in which tumor cells occupy an empty space.
It involves a dynamic interaction between tumor cells and the bone microenvironment.
In many breast cancer metastases, tumor-mediated signaling stimulates osteoclast activity and bone resorption. The resulting osteolysis releases growth factors from the bone matrix, which can further support tumor growth.
This creates a vicious cycle:
Tumor invasion → osteoclast activation → bone resorption → release of matrix-derived growth factors → tumor stimulation → further bone destruction.
Recent reviews continue to emphasize the importance of the osteoclast–osteoblast balance and the bone microenvironment in breast cancer skeletal metastasis. (PubMed)
This biological mechanism helps explain why breast cancer metastases can produce destructive lucent lesions.
But it does not explain every individual imaging appearance.
A metastasis may contain residual trabecular bone, reactive bone, sclerosis, mineralization, or treatment-related changes.
Consequently, a small internal osseous focus can mimic a sequestrum.
That is why the sequestral-like appearance should be regarded as an imaging morphology rather than a histologic diagnosis.
4. Epidemiology and Clinical Importance
Bone is one of the most important metastatic sites in advanced breast cancer.
The axial skeleton is particularly important, including:
Spine
Ribs
Pelvis
Sternum
The case source cites a large retrospective breast cancer cohort in which the spine was the most common skeletal metastatic site, with thoracic and lumbar vertebrae particularly represented.
Why does this matter clinically?
Because vertebral metastasis is not simply an imaging abnormality.
It can produce:
Persistent focal pain
Pathologic fracture
Vertebral collapse
Spinal instability
Epidural tumor extension
Spinal cord compression
Neurologic deficit
Hypercalcemia
Reduced quality of life
The imaging diagnosis therefore has direct consequences for treatment and emergency diagnosis.
5. Clinical Presentation: The Back Pain That Changed the Diagnosis
The patient in this case was a woman in her late twenties with chronic back pain.
The duration of pain alone could easily have encouraged a benign explanation.
But radiology should not evaluate back pain by duration alone.
Important clinical questions include:
Is the pain progressively worsening?
Is it worse at night?
Is it focal rather than diffuse?
Does it respond to conventional analgesics?
Is there radiation into the legs?
Is there numbness?
Is there weakness?
Are bowel or bladder symptoms present?
Is there fever?
Is there a known history of malignancy?
Has unexplained weight loss occurred?
Red flags become particularly important when imaging reveals an aggressive osseous lesion.
The combination of persistent focal pain + destructive bone lesion + known malignancy should substantially increase suspicion for metastatic disease.
The ACR approach to low back pain similarly emphasizes the importance of clinical red flags such as malignancy, infection, and fracture when deciding whether advanced imaging is appropriate. The case material cites the ACR Appropriateness Criteria in this context.
6. CT Imaging: The Most Important Examination for the Sequestralike Pattern
Figure 2. CT Axial Image
Figure 2. Axial CT demonstrates an approximately 2-cm lucent lesion in the right aspect of the T12 vertebral body with a central sequestralike osseous/calcific focus, cortical involvement, and mild adjacent soft-tissue extension.
Radiologic interpretation
The lesion is clearly lucent relative to the surrounding vertebral trabecular bone.
Within the lucent lesion is a relatively dense internal structure.
This is the classic setting in which a sequestral-like appearance becomes visually striking.
However, three findings deserve particular attention:
1. Lucent lesion
The lesion is predominantly osteolytic.
2. Cortical involvement
The cortex is not simply remodeled in an innocuous fashion; there is evidence of cortical involvement.
3. Soft-tissue extension
There is mild adjacent soft-tissue expansion.
The combination of these findings increases concern for an aggressive process.
The source case identifies the combination of lucent lesion + cortical involvement + soft-tissue extension as a major warning pattern.
This is where CT becomes particularly powerful.
MRI is superior for marrow and neural structures.
PET provides molecular information.
But CT excels at showing:
Cortical destruction
Trabecular architecture
Mineralization
Matrix
Internal osseous fragments
Lesion density
Soft-tissue mineralization
Subtle bone destruction
For a sequestral-like lesion, these structural details are critical.
7. Figure 3: Sagittal CT and the Importance of Lesion Location
Figure 3. Sagittal CT demonstrates the focal T12 vertebral-body lesion and its relationship to the vertebral architecture. The lesion contains a central sequestral-like structure and shows localized osseous destruction.
Radiologic interpretation
The sagittal reconstruction confirms that the lesion is centered in the T12 vertebral body.
This matters.
The lesion is not simply an incidental posterior-element abnormality.
Its vertebral-body location changes the differential diagnosis.
A careful CT review should assess:
Posterior vertebral wall
Pedicles
Laminae
Spinous process
Neural foramina
Epidural space
Vertebral height
Alignment
A lesion may be small but clinically dangerous if it compromises spinal stability or approaches neural structures.
The case source correctly emphasizes that lesion size alone does not determine risk. Location, structural integrity, and proximity to neural structures can be more clinically important.
8. Bone-RADS: From Pattern Recognition to Management
Modern radiology increasingly emphasizes structured management rather than simply assigning a descriptive diagnosis.
The Society of Skeletal Radiology introduced Bone-RADS for incidentally encountered solitary bone lesions on CT and MRI in adults.
The original framework includes four categories:
| Bone-RADS | Interpretation | General Management |
|---|---|---|
| 1 | Likely benign | Leave alone |
| 2 | Incompletely assessed | Different imaging modality |
| 3 | Indeterminate | Follow-up imaging |
| 4 | Suspicious or requires treatment | Biopsy and/or oncologic referral |
The original Bone-RADS publication specifically designed the system to connect imaging characteristics with management decisions. (PubMed)
In this case, the aggressive CT characteristics—particularly cortical involvement and soft-tissue extension—support a high-suspicion category under the framework used in the case material.
The original case therefore classified the lesion as Bone-RADS 4.
Importantly, Bone-RADS is not a substitute for clinical judgment.
Recent validation studies have shown that Bone-RADS can be useful for identifying lesions requiring further evaluation, but inter-reader agreement and specificity remain imperfect. (PubMed)
A 2025 study also evaluated a revised Bone-RADS approach, reflecting ongoing refinement of structured bone-lesion assessment. (PubMed)
Therefore:
Bone-RADS should support—not replace—expert radiology interpretation.
9. MRI: Defining Extent Rather Than Automatically Naming the Tumor
Figure 4. MRI Sagittal Sequences
Figure 4. Sagittal MRI demonstrates a T12 marrow lesion that is hypointense on T1-weighted imaging, relatively hyperintense on T2/STIR-type sequences, and associated with surrounding marrow signal abnormality.
Radiologic interpretation
The MRI findings indicate abnormal marrow replacement.
The lesion demonstrates:
Low T1 signal
Intermediate-to-high T2/STIR signal
Surrounding marrow edema
Enhancement
Local soft-tissue involvement
MRI is particularly valuable because it provides information that CT cannot fully characterize.
It can demonstrate:
Marrow replacement
Epidural extension
Paraspinal soft tissue
Neural foraminal involvement
Spinal canal compromise
Vertebral marrow edema
Relationship to the spinal cord
But MRI has a major limitation in this case.
It does not automatically distinguish osteoblastoma from metastasis.
The source case explicitly notes that MRI findings remained compatible with osteoblastoma and therefore did not independently establish the final diagnosis.
This is an important lesson:
Better imaging does not necessarily mean a definitive diagnosis.
MRI improves anatomic characterization.
It does not replace pathology, clinical context, or tumor-specific molecular imaging.
10. Figure 5: Axial Post-Contrast MRI
Figure 5. Axial post-contrast T1-weighted MRI demonstrates enhancement within the T12 lesion with surrounding marrow abnormality, supporting the presence of vascularized or viable tissue.
Radiologic interpretation
Contrast enhancement indicates viable tissue within or around the lesion.
The important questions are:
Is enhancement diffuse or peripheral?
Is there a solid component?
Is there an epidural component?
Is there paraspinal extension?
Is the posterior cortex preserved?
Is the spinal canal compromised?
In this case, the enhancement pattern was not specific enough to separate osteoblastoma from metastatic breast cancer.
This is why radiology interpretation must remain probabilistic.
11. Differential Diagnosis of a Sequestralike Vertebral Lesion
A sequestralike appearance should generate a broad but organized differential diagnosis.
Major considerations
11.1 Osteomyelitis
Infection is one of the classic considerations.
A true sequestrum is strongly associated with chronic osteomyelitis.
However, infection should be evaluated in conjunction with:
Fever
Elevated inflammatory markers
Risk factors
Disc-space involvement
Endplate destruction
Paraspinal abscess
Epidural abscess
The presence of a sequestral-like structure alone does not establish osteomyelitis.
11.2 Osteoid Osteoma
Osteoid osteoma can contain a mineralized nidus within a lucent region.
However, its typical size, location, pain characteristics, and cortical appearance must be considered.
11.3 Osteoblastoma
Osteoblastoma becomes particularly relevant in young patients with spinal lesions.
It can be larger and more locally aggressive than osteoid osteoma.
11.4 Langerhans Cell Histiocytosis
LCH can produce lytic osseous lesions and may enter the differential diagnosis in young patients.
11.5 Metastasis
Metastatic disease becomes increasingly important when there is:
Known malignancy
Multiple lesions
Cortical destruction
Soft-tissue extension
Aggressive marrow replacement
11.6 Primary Bone Lymphoma
Lymphoma can produce destructive or permeative bone lesions and should be considered when the imaging pattern and clinical context are appropriate.
11.7 Fibrosarcoma and Other Aggressive Bone Tumors
Rare primary malignant bone tumors can also mimic this pattern.
The source case additionally discusses several other possible mimics, including chondroid lesions, intraosseous lipoma, hemangioma, fibrous dysplasia, radiation necrosis, and postoperative change.
The key principle is:
Do not let the word “sequestralike” prematurely close the differential diagnosis.
12. The Diagnostic Turning Point: ER-Positive Breast Cancer
The most important change in this case was not another CT sequence.
It was clinical information.
The patient was diagnosed with:
ER-positive / PR-positive / HER2-negative invasive ductal carcinoma.
This fundamentally changed the prior probability of metastatic disease.
Before the breast cancer diagnosis, the diagnostic question was:
“What benign or malignant primary bone tumor could produce this appearance in a young woman?”
After the breast cancer diagnosis, the question became:
“Could this vertebral lesion represent metastatic breast cancer?”
That is a very different probability landscape.
The same imaging appearance can represent different diseases depending on the patient's clinical context.
This is one of the central principles of Bayesian radiology interpretation.
Imaging morphology provides the likelihood.
Clinical history provides the prior probability.
Additional imaging and pathology refine the posterior probability.
This is why high-level radiology interpretation is more than visual pattern recognition.
13. Figure 6: 18F-FES PET/CT Axial Imaging
Figure 6. Axial 18F-FES PET/CT demonstrates increased radiotracer uptake corresponding to the T12 vertebral lesion.
Radiologic interpretation
18F-FES, or 16α-[18F]fluoro-17β-estradiol, is an estrogen receptor-targeted PET tracer.
Unlike 18F-FDG, which primarily reflects glucose metabolism, 18F-FES PET/CT provides information about functional estrogen receptor expression.
This distinction is clinically important.
The two examinations answer different questions:
| PET/CT | Principal Biological Question |
|---|---|
| 18F-FDG | Is the lesion metabolically active? |
| 18F-FES | Does the lesion demonstrate functional ER expression? |
| 18F-NaF | Is there increased bone turnover? |
Current SNMMI/EANM guidance recognizes ^18F-FES PET as a standardized molecular imaging approach for ER imaging in breast cancer. (PubMed)
The case therefore moved beyond structural medical imaging into molecular imaging.
14. Figure 7: Sagittal 18F-FES PET/CT and the Discovery of Additional Bone Disease
Figure 7. Sagittal 18F-FES PET/CT demonstrates increased uptake at T12 and additional skeletal abnormalities that become apparent when the entire examination is reviewed.
Radiologic interpretation
This is where the diagnostic story changes from a local lesion to systemic disease.
The original CT focused attention on T12.
The molecular PET/CT examination demonstrated that the patient had additional skeletal involvement.
The clinical question was therefore no longer:
“What is this T12 lesion?”
It became:
“What is the extent and biological phenotype of the patient's metastatic breast cancer?”
This distinction has direct treatment implications.
A 2024 study involving 344 patients with suspected or known recurrent/metastatic ER-positive breast cancer found that 18F-FES PET/CT changed management in 35% of patients, illustrating that the examination can have consequences beyond simply improving image interpretation. (PubMed)
15. Why 18F-FES PET/CT Is Particularly Interesting in ER-Positive Disease
The value of 18F-FES PET/CT lies in its ability to visualize a functional tumor characteristic.
Tissue pathology tells us whether the sampled tumor expresses ER.
18F-FES PET/CT asks a complementary question:
Where in the body is functional ER expression demonstrated?
This can be particularly relevant in metastatic disease because tumor biology may vary between lesions.
A 2024 SNMMI/EANM guideline summary notes that 18F-FES PET can help assess ER expression, clarify equivocal staging or restaging findings, and in selected settings contribute to treatment planning. (PubMed)
More recently, a 2025 systematic review and meta-analysis reported that patients with positive 18F-FES PET findings were substantially more likely to benefit from endocrine therapy than patients with negative findings, although the clinical application must remain individualized. (PubMed)
A 2026 meta-analysis further examined ER-targeted PET as a predictor of endocrine therapy response in metastatic breast cancer, reflecting the rapidly expanding role of molecular imaging in precision oncology. (PubMed)
However, an important limitation must be remembered:
18F-FES uptake does not by itself establish histologic diagnosis.
Imaging findings must still be integrated with CT, MRI, pathology, clinical history, and treatment context.
16. CT, MRI, and PET: Three Different Questions
One of the most useful ways to remember this case is:
CT asks: “What does the bone look like?”
CT excels at:
Cortical destruction
Mineralization
Sequestralike structures
Trabecular architecture
Matrix
Bone stability
MRI asks: “How far has the lesion extended?”
MRI excels at:
Marrow replacement
Epidural extension
Neural compression
Soft tissue
Spinal canal involvement
Paraspinal disease
PET asks: “What biological behavior does the lesion demonstrate?”
^18F-FES PET/CT provides:
ER-targeted molecular information
Whole-body distribution
Lesion-to-lesion biological assessment
Additional metastatic mapping
This can be summarized as:
CT shows structure. MRI shows extent. PET shows biology.
That conceptual framework is highly useful in modern oncologic imaging.
17. Figure 8: Integrated Diagnostic Algorithm
Figure 8. Integrated diagnostic pathway showing the progression from chronic back pain to CT detection of a T12 lucent lesion, MRI characterization, recognition of ER-positive/PR-positive/HER2-negative breast cancer, 18F-FES PET/CT evaluation, and final diagnosis of breast cancer bone metastasis.
This figure demonstrates why multimodality imaging should not be viewed as a collection of independent examinations.
Each modality answers a different clinical question.
The diagnostic sequence is approximately:
Symptoms → CT → lesion characterization → MRI → clinical correlation → molecular imaging → systemic staging → treatment planning
The crucial step is clinical integration.
18. Figure 9: The Central Radiology Principle
Figure 9. Diagnostic anchoring concept: a sequestral-like appearance should be interpreted together with patient history, lesion morphology, and tumor biology rather than treated as a disease-specific sign.
This is perhaps the most important educational message in the entire case.
A radiologist may recognize a familiar imaging pattern quickly.
That is useful.
But pattern recognition becomes dangerous when it becomes pattern fixation.
The correct sequence is:
Recognize the pattern.
Generate the differential diagnosis.
Assess aggressive features.
Review clinical history.
Estimate disease probability.
Select the appropriate next examination.
Integrate all available evidence.
Recommend management or tissue diagnosis when necessary.
19. Diagnosis Workflow for a Similar Patient
20. Treatment of Breast Cancer Bone Metastasis
Treatment should not be selected from the CT image alone.
Management depends on:
ER status
PR status
HER2 status
Menopausal status
Extent of metastatic disease
Visceral metastases
Bone burden
Fracture risk
Spinal instability
Neurologic compression
Pain
Previous treatment
Performance status
Molecular characteristics
For ER-positive/HER2-negative metastatic breast cancer, endocrine therapy is an important component of systemic treatment, and targeted therapies such as CDK4/6 inhibitors may be incorporated depending on the clinical setting.
Bone-directed therapy may include agents such as:
Bisphosphonates
Denosumab
These therapies are used to reduce skeletal complications in appropriate patients.
Radiation therapy may be considered for painful or locally threatening lesions.
Surgery or stabilization may be required when there is:
Mechanical instability
Pathologic fracture
Significant spinal cord compression
Severe neurologic compromise
Structural instability
The case source specifically emphasizes the danger of allowing vertebral metastatic disease to progress from vertebral destruction to collapse, pathologic fracture, spinal cord compression, weakness, and gait disturbance.
21. Prognosis: Bone Metastasis Does Not Mean One Uniform Outcome
The prognosis of metastatic breast cancer varies substantially.
Important factors include:
ER status
PR status
HER2 status
Tumor biology
Response to systemic therapy
Bone-only versus visceral disease
Number and distribution of metastases
Patient performance status
Treatment options
Therefore, the statement “bone metastasis means a poor prognosis” is too simplistic.
Modern breast cancer oncology increasingly uses molecularly tailored systemic therapy.
Patients with hormone receptor-positive disease may have prolonged disease control with sequential systemic treatments, particularly when metastatic disease is predominantly osseous and responds well to therapy.
The case source similarly emphasizes that prognosis cannot be determined simply from the presence of bone metastasis.
22. Emergency Diagnosis: When Back Pain Becomes a Medical Emergency
A vertebral metastasis can become an emergency when it produces spinal cord or cauda equina compromise.
Warning symptoms include:
New leg weakness
Progressive numbness
Gait disturbance
Saddle anesthesia
New urinary retention
New urinary or fecal incontinence
Severe progressive back pain
Rapid neurologic deterioration
These symptoms require urgent medical evaluation.
In a patient with known malignancy, suspected spinal cord compression should never be treated as routine mechanical back pain.
MRI is generally central to evaluating neural compression and epidural disease.
23. Key Radiology Pitfalls
Pitfall 1: “Sequestralike appearance means osteomyelitis.”
Incorrect.
It is a radiologic pattern.
Pitfall 2: “A young patient cannot have metastasis.”
Incorrect.
Age changes probability but does not eliminate malignancy.
Pitfall 3: “Central calcification means osteoblastoma.”
Incorrect.
Mineralized or osseous internal structures occur in multiple lesions.
Pitfall 4: “MRI gives the final diagnosis.”
Not necessarily.
MRI is excellent for lesion extent and neural structures but may not distinguish histologically similar entities.
Pitfall 5: “A solitary lesion on CT means solitary disease.”
Not necessarily.
Whole-body imaging may identify additional lesions.
Pitfall 6: “A PET-positive lesion is automatically metastatic.”
Not necessarily.
Tracer uptake must be interpreted according to the tracer, tumor biology, morphology, and clinical context.
24. The Most Important Clinical Lesson
The most important lesson is not that breast cancer can metastasize to the spine.
That is already well established.
The important lesson is that metastatic breast cancer can present with an imaging morphology that strongly resembles a primary benign bone tumor.
In this case:
Young age + spinal lesion + central mineralized focus → osteoblastoma seemed reasonable.
Then:
Breast cancer diagnosis → metastatic disease probability increased.
Then:
ER-positive biology + ^18F-FES uptake → molecular imaging supported the metastatic interpretation.
Finally:
Additional skeletal lesions → systemic metastatic disease became the most coherent explanation.
This is diagnostic reasoning in action.
25. Key Takeaways
1. Sequestralike appearance is not a diagnosis.
It is an imaging pattern characterized by a relatively dense internal osseous or calcific structure within a lucent lesion.
2. CT is particularly important.
CT is excellent for evaluating the cortical destruction, mineralization, matrix, and internal osseous architecture that create the sequestral-like appearance.
3. Aggressive features matter.
Lucent lesion + cortical involvement + soft-tissue extension should trigger a careful assessment for malignancy or another aggressive process.
4. MRI complements CT.
MRI defines marrow and soft-tissue extent and evaluates epidural and neural involvement.
5. Clinical history changes probability.
A vertebral lesion in a healthy young adult is not interpreted in the same way as the same lesion in a patient with breast cancer.
6. ER-positive disease creates an opportunity for molecular imaging.
18F-FES PET/CT can provide functional ER information and may clarify staging or restaging in appropriate patients. (PubMed)
7. PET is not a replacement for pathology.
Molecular imaging should be integrated with morphology, clinical information, and histopathology when indicated.
8. Rare imaging patterns require broad differential diagnosis.
A memorable sign can help diagnosis—but it can also create diagnostic anchoring.
26. Frequently Asked Questions
Is sequestralike appearance specific for osteomyelitis?
No.
A sequestralike appearance can occur in infection, benign tumors, malignant tumors, metastases, inflammatory disease, and treatment-related changes.
Can breast cancer metastasis look like osteoblastoma?
Yes.
This case demonstrates exactly that diagnostic challenge. The patient's age and T12 lesion morphology initially favored osteoblastoma, but the subsequent diagnosis of ER-positive/PR-positive/HER2-negative breast cancer changed the probability assessment.
Is CT or MRI better for sequestral-like appearance?
For identifying the small internal osseous or calcific structure itself, CT is particularly valuable.
MRI is better for evaluating marrow involvement, soft tissue, epidural disease, and neural structures.
What is Bone-RADS 4?
Bone-RADS 4 represents a suspicious lesion or a lesion requiring treatment consideration under the original Bone-RADS framework, generally prompting biopsy and/or oncologic referral. (PubMed)
Why was 18F-FES PET/CT performed?
Because the patient had ER-positive breast cancer and an indeterminate vertebral lesion. 18F-FES PET/CT can visualize functional ER expression and help assess the distribution of ER-positive disease.
Is 18F-FES PET the same as FDG PET?
No.
FDG PET primarily evaluates glucose metabolism.
18F-FES PET evaluates functional estrogen receptor expression.
Can 18F-FES PET prove that a bone lesion is metastatic?
Not by itself.
The interpretation requires correlation with CT, MRI, pathology, clinical history, and the known tumor phenotype.
Can a small vertebral metastasis be dangerous?
Yes.
Risk depends not only on size but also on location, cortical destruction, vertebral stability, epidural extension, and neural compression.
When is back pain an emergency?
New weakness, progressive sensory loss, gait disturbance, bowel or bladder dysfunction, or suspected spinal cord compression requires urgent medical evaluation.
Does bone metastasis always mean a very short survival?
No.
Prognosis varies widely according to tumor biology, receptor status, disease distribution, treatment response, and overall health.
Quiz
Question 1
A woman in her late twenties has chronic back pain. CT demonstrates an approximately 2-cm lucent T12 vertebral-body lesion containing a small central osseous structure, with cortical involvement and mild soft-tissue extension. Which Bone-RADS category is most appropriate under the framework used in this case?
A. Bone-RADS 1
B. Bone-RADS 2
C. Bone-RADS 3
D. Bone-RADS 4
E. Bone-RADS 5
Correct answer: D. Bone-RADS 4
Explanation
The lesion has aggressive imaging features, particularly cortical involvement and soft-tissue extension. These findings make it inappropriate to simply dismiss the lesion as a benign incidental finding. The case source classified the lesion as Bone-RADS 4, for which biopsy and/or oncologic evaluation is generally considered.
The original Bone-RADS framework contains four categories; Bone-RADS 5 is not part of the original system.
Question 2
The same patient is subsequently diagnosed with ER-positive, PR-positive, HER2-negative invasive ductal breast carcinoma. The T12 lesion remains indeterminate after MRI. Which additional imaging examination is particularly relevant to the tumor biology?
A. Repeat plain radiography only
B. Noncontrast head CT
C. 18F-FES PET/CT
D. Ultrasound of the lumbar spine
E. Repeat CT in six months regardless of clinical findings
Correct answer: C. 18F-FES PET/CT
Explanation
^18F-FES PET/CT targets functional estrogen receptor expression and can provide whole-body molecular information in ER-positive breast cancer.
The case demonstrated increased ^18F-FES uptake at T12 and additional skeletal lesions.
Current SNMMI/EANM guidance supports standardized use of ^18F-FES PET for ER imaging in appropriately selected breast cancer patients. (PubMed)
Question 3
Which statement about sequestral-like appearance is most accurate?
A. It is pathognomonic for osteomyelitis.
B. It excludes metastatic disease.
C. It is more specific for osteoblastoma than metastasis.
D. It describes an imaging pattern in which a relatively dense osseous or calcific structure is seen within a lucent bone lesion.
E. It automatically establishes the histologic diagnosis.
Correct answer: D
Explanation
Sequestralike appearance is an imaging pattern rather than a disease-specific diagnosis.
It may occur in osteomyelitis, Langerhans cell histiocytosis, benign bone tumors, metastatic disease, lymphoma, and other conditions. CT is particularly useful for demonstrating the small internal osseous or mineralized component.
A Practical Reporting Template for Radiologists
When encountering a similar lesion, a structured report might include:
Location:
T12 vertebral body.
Morphology:
Approximately 2-cm lucent lesion with internal osseous/mineralized sequestral-like focus.
Aggressive features:
Cortical involvement and mild adjacent soft-tissue extension.
MRI correlation:
T1 hypointensity, T2/STIR hyperintensity, enhancement, and surrounding marrow edema.
Clinical correlation:
Known ER-positive/PR-positive/HER2-negative invasive ductal breast carcinoma.
Impression:
Aggressive solitary vertebral lesion. Sequestral-like appearance is nonspecific. In the setting of known breast malignancy, metastatic disease should be strongly considered. Recommend appropriate oncologic/molecular imaging evaluation and tissue sampling when clinically indicated.
This style is preferable to simply writing:
“Possible osteoblastoma.”
The former communicates risk and management implications.
Why This Case Matters Beyond Breast Cancer
This case provides a broader lesson applicable to all medical imaging.
Radiologists frequently encounter lesions that resemble familiar entities.
The danger arises when recognition becomes premature closure.
A strong radiologist does not stop at:
“This looks like osteoblastoma.”
The next questions are:
Does the location fit?
Does the age fit?
Does the clinical history fit?
Are there aggressive features?
Could metastatic disease produce the same appearance?
Is there a better examination for answering the biological question?
That reasoning process is increasingly important in modern oncology, where structural imaging, functional imaging, molecular imaging, pathology, and genomic information are becoming integrated into a single diagnostic pathway.
Conclusion
A small T12 vertebral lesion in a young woman may initially look like a benign or locally aggressive primary bone tumor.
In this case, the approximately 2-cm lucent lesion contained a central sequestral-like structure and demonstrated cortical involvement and soft-tissue extension. The patient's young age and morphology made osteoblastoma a reasonable initial consideration.
MRI demonstrated marrow involvement, enhancement, and surrounding edema but did not provide a definitive histologic diagnosis.
The decisive change came from clinical context.
Once ER-positive, PR-positive, HER2-negative invasive ductal breast carcinoma was recognized, metastatic breast cancer became a major diagnostic consideration.
18F-FES PET/CT then provided a biological dimension to the evaluation, demonstrating increased uptake at T12 and additional skeletal lesions.
The case therefore illustrates a fundamental principle of advanced medical imaging:
The most convincing diagnosis is not necessarily the lesion that looks most familiar. It is the diagnosis that best integrates morphology, anatomy, clinical probability, tumor biology, and the total imaging evidence.
For radiologists, the practical lesson is simple:
Sequestralike appearance is a pattern.
CT defines the bone architecture.
MRI defines the extent.
PET can define biological phenotype.
Clinical history determines probability.
And when those elements point in the same direction, the diagnostic pathway becomes considerably more powerful.
In the era of precision oncology, the best radiology interpretation is therefore not merely a description of what is visible.
It is an explanation of what the imaging means for the patient—and what should happen next.
Medical Disclaimer
This article is intended for medical education and does not constitute individualized medical advice, diagnosis, or treatment. Imaging findings must be interpreted in the context of the patient's clinical history, physical examination, laboratory findings, pathology, and multidisciplinary assessment. Patients with persistent or progressive back pain, neurologic symptoms, or a known malignancy should consult an appropriate medical specialist.
References
[1] T. A. Hutchins, M. Peckham, L. M. Shah, et al., “ACR Appropriateness Criteria® Low Back Pain: 2021 Update,” Journal of the American College of Radiology, vol. 18, no. 11S, pp. S361–S379, 2021. DOI: 10.1016/j.jacr.2021.08.002.
[2] C. Y. Chang, H. W. Garner, S. Ahlawat, et al., “Society of Skeletal Radiology—white paper: Guidelines for the diagnostic management of incidental solitary bone lesions on CT and MRI in adults: Bone-RADS,” Skeletal Radiology, vol. 51, no. 9, pp. 1743–1764, 2022. DOI: 10.1007/s00256-022-04022-8.
[3] K. I. Atesok, B. A. Alman, E. H. Schemitsch, A. Peyser, and H. Mankin, “Osteoid osteoma and osteoblastoma,” Journal of the American Academy of Orthopaedic Surgeons, vol. 19, no. 11, pp. 678–689, 2011. DOI: 10.5435/00124635-201111000-00004.
[4] W.-Z. Chen, J.-F. Shen, Y. Zhou, et al., “Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer,” Scientific Reports, vol. 7, art. no. 11325, 2017. DOI: 10.1038/s41598-017-11700-4.
[5] M. V. Krasnokutsky, “The button sequestrum sign,” Radiology, vol. 236, no. 3, pp. 1026–1027, 2005. DOI: 10.1148/radiol.2363031294.
[6] F. Jennin, V. Bousson, C. Parlier, et al., “Bony sequestrum: A radiologic review,” Skeletal Radiology, vol. 40, no. 8, pp. 963–975, 2011. DOI: 10.1007/s00256-010-0975-4.
[7] D. Mankoff, S. Balogová, L. Dunnwald, et al., “Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[18F]Fluoro-17β-Estradiol PET,” Journal of Nuclear Medicine, vol. 65, no. 2, pp. 221–223, 2024. DOI: 10.2967/jnumed.123.266938.
[8] J. Ryu, J. Hyung, S. Han, et al., “Impact of 18F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer,” Journal of Nuclear Medicine, vol. 65, no. 11, pp. 1689–1694, 2024. DOI: 10.2967/jnumed.124.267913.
[9] A. S. Parihar, S. Vaz, S. Sutcliffe, et al., “18F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis,” Journal of Nuclear Medicine, vol. 66, no. 5, pp. 692–699, 2025. DOI: 10.2967/jnumed.124.269163.
[10] J. M. Specht, J. J. L. van Geel, S. Song, et al., “The Role of Estrogen Receptor-Targeted PET with 16α-18F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis,” Journal of Nuclear Medicine, vol. 67, no. 1, pp. 36–42, 2026. DOI: 10.2967/jnumed.125.270763.
Recommended Reading
Bone-RADS and structured evaluation of incidental solitary bone lesions.
Radiologic differential diagnosis of sequestralike and button-sequestrum appearances.
^18F-FES PET/CT for estrogen receptor imaging in breast cancer.
Molecular imaging and endocrine-treatment response prediction.
Multimodality imaging of spinal metastases.
Imaging assessment of spinal instability and metastatic epidural disease.
Comments
Post a Comment